An epigenetic difference in twins explains different risk of breast cancer

October 17, 2012
Two monozygotic twins and Dr. Manel Esteller, along a collaborator.

Monozygotic twins have the same genome, that is, the same DNA molecule in both siblings. Despite being genetically identical, both twins may have different diseases at different times. This phenomenon is called "twin discordance". But how can people who have the same genetic sequence present different pathologies and at different ages? The explanation partly lies in the fact that the chemical signals added in the DNA to "switch off" or "switch on" genes can be different. These signals are known as epigenetic marks.

The research team led by Manel Esteller, director of the Cancer Epigenetics and Biology Program at the Bellvitge Biomedical Research Institute (IDIBELL), Professor of Genetics at the University of Barcelona and ICREA researcher, has identified an epigenetic change in the twin who will develop breast cancer but not in her healthy one. The finding has been advanced this week in the journal Carcinogenesis.

The research group led by Dr. Esteller studied the levels of (the best known epigenetic mark) in the blood of 36 pairs of twins diagnosed with breast cancer or healthy. Researchers analyzed half a million pieces of the genome in each twin and compared them with each other, and they found that women who have developed showed a pathological gain of methylation in the DOK7 gene. " an epigenetic alteration associated with an increased risk of breast cancer can be detected in the sick twin a few years before the clinical diagnosis", said Dr. Esteller about the research results.

The next step for the researchers will be knowing the exact function of the DOK7 gene. "We believe it is a regulator of , an antitumor already used for the treatment of breast cancer. If DOK7 performs this function, new studies to test drugs with tumour chemopreventive effects in breast cancer could be planned in the future", concludes the research coordinator.

Explore further: Researchers complete the first epigenome in Europe

More information: Heyn H, Carmona FJ, Gomez A, Ferreira HJ, Bell JT, Sayols S, Ward K, Stefansson OA, Moran S, Sandoval J, Eyfjord JE, Spector TD, Esteller M. DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker. Carcinogenesis. Published online October 10 2012.

Related Stories

Researchers complete the first epigenome in Europe

May 30, 2012
A study led by Manel Esteller, director of the Epigenetics and Cancer Biology Program at the Bellvitge Biomedical Research Institute (IDIBELL), professor of genetics at the University of Barcelona and ICREA researcher, has ...

Researchers characterize epigenetic fingerprint of 1,628 people

June 2, 2011
Until a decade, it was believed that differences between people were due solely to the existence of genetic changes, which are alterations in the sequence of our genes. The discoveries made during these last ten years show ...

Epigenetics emerges powerfully as a clinical tool

September 12, 2012
A study coordinated by Manel Esteller, published in Nature Reviews Genetics, highlights the success of this area of research to predict the behavior and weaknesses of tumors.

Adult stem cells change their epigenome to generate new organs

October 2, 2012
A study developed by researchers at the IDIBELL, led by Manel Esteller, has identified epigenetic changes that occur in adult stem cells to generate different tissues of the human body.

Study: The epigenome of newborns and centenarians is different

June 11, 2012
What happens in our cells after one hundred years? What is the difference at the molecular level between a newborn and a centenary? Is it a gradual or a sudden change? Is it possible to reverse the aging process? What are ...

Twin study reveals epigenetic alterations of psychiatric disorders

September 21, 2011
In the first study to systematically investigate genome-wide epigenetic differences in a large number of psychosis discordant twin-pairs, research at the Institute of Psychiatry (IoP) at King's College London provides further ...

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.